0001193125-23-080474.txt : 20230327 0001193125-23-080474.hdr.sgml : 20230327 20230327161904 ACCESSION NUMBER: 0001193125-23-080474 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20230322 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230327 DATE AS OF CHANGE: 20230327 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AVITA Medical, Inc. CENTRAL INDEX KEY: 0001762303 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 202578762 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39059 FILM NUMBER: 23764753 BUSINESS ADDRESS: STREET 1: 28159 AVENUE STANFORD STREET 2: SUITE 220 CITY: VALENCIA STATE: CA ZIP: 91355 BUSINESS PHONE: 661-568-1317 MAIL ADDRESS: STREET 1: 28159 AVENUE STANFORD STREET 2: SUITE 220 CITY: VALENCIA STATE: CA ZIP: 91355 FORMER COMPANY: FORMER CONFORMED NAME: Avita Therapeutics, Inc. DATE OF NAME CHANGE: 20200630 FORMER COMPANY: FORMER CONFORMED NAME: Avita Medical, Ltd. DATE OF NAME CHANGE: 20181218 8-K 1 d468715d8k.htm 8-K 8-K
false 0001762303 0001762303 2023-03-22 2023-03-22

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 22, 2023

 

 

AVITA Medical, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-39059   85-1021707
(State or other jurisdiction
of incorporation)		   (Commission
File Number)		   (IRS Employer
Identification No.)

 

28159 Avenue Stanford, Suite 220, Valencia, CA 91355   661.367.9170
(Address of principal executive offices, including Zip Code)   (Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading
Symbol(s)

  

Name of each exchange
on which registered

Common Stock, par value $0.0001 per share   RCEL   The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934. Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(d) Election of Directors

On March 23, 2023, AVITA Medical, Inc. (the “Company”) issued a press release announcing the appointment of Robert McNamara to its Board of Directors (the “Board”), effective April 1, 2023, to serve until the Company’s 2023 Annual Meeting of Stockholders. The Board has not yet determined to appoint Mr. McNamara to any committees of the Board. A copy of the press release is attached hereto as Exhibit 99.1.

The Board has determined that Mr. McNamara meets the independence standards adopted by the Board in compliance with Item 407(a) of Regulation S-K. Mr. McNamara does not have (i) any arrangement or understanding with any other person pursuant to which he was appointed as a director, or (ii) any family relationship with any director or executive officer of the Company or any person nominated or chosen by the Company to become a director or executive officer. Mr. McNamara does not have any direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.

Mr. McNamara is a senior executive with over 25 years of leadership experience in public and privately held companies in the medical device and technology industries. He is currently a member of the Board of Directors and Chair of Audit Committee for each of Axonics, Inc. and Alpha Teknova, Inc. Additionally, Mr. McNamara is a member of the Board of Directors and Chair of Compensation Committee for Xtant Medical Holdings, Inc. Prior to these appointments, Mr. McNamara served as Executive Vice President, Chief Financial Officer of LDR Holding/Spine, Inc. Prior to this role, he served as the Chief Financial Officer of three publicly traded medical device companies: Accuray Incorporated, Somnus Medical Technologies, and Target Therapeutics Inc. Mr. McNamara holds a Bachelor of Science in Accounting from the University of San Francisco and an MBA from The Wharton School, University of Pennsylvania.

In connection with his appointment to the Board, the Company entered into an Engagement Letter dated March 22, 2023, with Mr. McNamara, which provides for Mr. McNamara to receive cash in the amount of $70,000 annually, subject to shareholder approval, as consideration for his Board services. To the extent that Mr. McNamara is appointed to one or more committees of the Board, additional consideration for his services will be negotiated. Mr. McNamara will also receive an initial stock grant equal in value to $210,000 with 30% granted as stock options and 70% granted as restricted stock units, along with an annual equity compensation component equal in value to $105,000 with 30% granted as options and 70% granted as restricted stock units, the foregoing also being subject to shareholder approval.

A copy of Mr. McNamara’s Engagement Letter is attached hereto as Exhibit 10.1 and is incorporated herein by reference. In connection with his services on the Board, the Company also entered into an indemnification agreement with Mr. McNamara on the Company’s standard form of indemnification agreement.

 

Item 8.01

Other Events

The Board has determined that the Company’s 2023 Annual Meeting of Stockholders shall be held at 3:00 pm Pacific Daylight Time on Tuesday, June 6, 2023 (being 8:00 am Australian Eastern Standard Time on June 7, 2023), via a live audio webcast.

 

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits

 

Exhibit
No.		   

Description of Exhibit

10.1    Engagement Letter dated March 22, 2023, between AVITA Medical, Inc. and Mr. Robert McNamara.
99.1    AVITA Medical Appoints New Non-Executive Member to the Board of Directors
104    Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: March 27, 2023

 

AVITA MEDICAL, INC.
By:  

/s/ Donna Shiroma

Name:   Donna Shiroma
Title:   General Counsel
 EX-10.1 2 d468715dex101.htm EX-10.1 EX-10.1

Exhibit 10.1

 

LOGO

March 22, 2023

Robert McNamara

56 Politzer Drive

Menlo Park, CA 94025

 

Re:

Appointment to Board of Directors

Dear Mr. McNamara:

I am pleased to confirm our offer regarding your appointment as a member of the Board of Directors of AVITA Medical Inc., a Delaware corporation (the “Company”), which will commence with effect on April 1, 2023 (the “Effective Date”), on the following terms:

 

1.

Position.

Your position as a Director of the Company will require formal acceptance of this appointment, by executing this letter agreement as of a date no later than March 28, 2023. Your term as a Director will commence on the Effective Date and you will be subject to annual re -election by the shareholders at the Company’s annual shareholder meeting which takes place on or around June of each year.

 

2.

Duties.

(a) As a non-executive director your duties involve commitment of your time to board meetings. We currently have four scheduled meetings per year which is subject to re -examination next year in which the frequency of the meetings may increase, plus additional board meetings, including strategy meetings. Additionally, there are committee meetings to which you may be appointed and we currently have four scheduled meetings per year per committee which is subject to re-examination next year in which the frequency of the meetings may increase. Whilst there is a clear need for in-person meetings, during unforeseen events or additional meetings, your attendance may be requested via teleconferencing.

(b) The Company understands and agrees that during your term as a Director you may serve in other capacities for the Company, including as an executive, consultant or advisor, and that you may also serve in like capacities for other companies not affiliated with AVITA Medical that are not Company competitors, subject to your obligations contained in this letter agreement. Any potential new appointments should be discussed with the Board Chair prior to acceptance, to allow consideration of matters including conflict of interest, and the time you can devote to your position as a non-executive director of AVITA Medical.

 

AVITA Medical

28159 Avenue Stanford, Suite 220 Valencia, CA 91355

P +1(661) 367-9170 l f +1 (661) 367-9180 l avitamedical.com

LOGO

 

3.

Compensation.

In consideration for your services to the Company as a non-executive Director, your current base compensation, which is subject to shareholder approval at the annual shareholder meeting, is US $70,000 annually with additional paid membership of one or more committees that will be discussed with you in due course. Cash remuneration for board directors is reviewed periodically by an outside consulting firm with reference to peer company compensation, and is subject to shareholder approval. You will receive an initial grant component of your compensation equal in value to $210,000 with 30% granted as options and 70% granted as restricted stock units along with an annual equity component of your compensation equal in value to $105,000 with 30% granted as options and 70% granted as restricted stock units.

 

4.

Expenses.

As a non-executive Director you are entitled to reimbursement for reasonable company -related expenditures incurred by you, including your travel to and from Board meetings, after receipt by the Company from you of an itemized expense report, together with receipts or other reasonable proof of such expenses. Travel is usually coordinated through the office of the CEO.

 

5.

Representations and Warranties.

(a) You represent and warrant that (i) your performance of your obligations under this letter agreement will not infringe any intellectual property, publicity or privacy rights of any third party, (ii) neither your advisory relationship with the Company, nor the performance of. your obligations hereunder, will conflict with or result in a breach of any third-party agreement by which you are currently bound, and (iii) your performance of your obligations under this letter agreement will not contain any defamatory or libelous material or material that discloses private or personal matters concerning any party, without that party’s consent.

(b) You further understand that your role as a Director will be that of an independent contractor and that you will not be an agent, employee or representative of the Company. You further understand that you will have no authority to enter into contracts or create obligations on the Company’s behalf. You acknowledge that you will not be eligible for any employee benefits and that the Company will not make any tax withholdings on your behalf. You agree that you are obligated to report as income all consideration that you receive in connection with this letter agreement, and you agree to pay any applicable self-employment and other taxes thereon, if any. You further agree to indemnify the Company and hold it harmless to the extent of any obligation imposed on the Company (i) to pay withholding taxes or similar items or (ii) resulting from your being determined not to be an independent contractor. All compensation paid to you shall be reported by the Company to the Internal Revenue Service and any applicable state tax authorities on a Form 1099 or other applicable form.

 

AVITA Medical

28159 Avenue Stanford, Suite 220 Valencia, CA 91355

P +1(661) 367-9170 l f +1 (661) 367-9180 l avitamedical.com

LOGO

 

6.

Confidential Information.

You agree that you will (i) hold in strictest confidence the Company’s proprietary information and trade secrets and all other information made known to you in connection with your relationship with the Company as a Director that has or could have commercial value or other utility in the Company’s business or prospective business (collectively, the “Confidential Information”), and (ii) not use the Confidential Information except in connection with your relationship with the Company as a Director.

The Confidential Information will not include information that you can establish is or was (i) received by you without an obligation of confidentiality from an unrelated third party that is not under an obligation of confidentiality to the Company and that has a legal right to disclose it, (ii) generally known or available in the industry or to the general public either (A) prior to the Company’s disclosure of such information to you or (B) after the Company’s disclosure of such information to you through no action or inaction by you, or (iii) required to be disclosed by applicable law, by order of court or the rules, regulations or order of any governmental agency.

You agree that you will not improperly use or disclose any proprietary information or trade secrets received by you from any third party in connection with your relationship with the Company as a Director. You recognize that the Company has received and in the future will receive confidential and proprietary information from third parties and that the Company will have a duty to maintain the confidentiality of such information and to use it only for certain limited purposes. You agree to hold all such confidential and proprietary information in the strictest confidence, and you further agree that you will neither disclose it to any person, firm or corporation nor use it in a manner that is inconsistent with the Company’s obligations to such third parties.·

To the extent that your service to the Company results directly in the creation of any new Intellectual Property (as defined below), you agree that, as between you and the Company, the Company shall own the rights to such new Intellectual Property if such Intellectual Property (i) is developed using the equipment, facilities, supplies or Confidential Information of the Company, or (ii) results from or is suggested by work performed by you on behalf of the Company, but only if you are explicitly engaged in performing direct work for the Company. For the purposes of this section, “Intellectual Property” means any original works of authorship, inventions, concepts, improvements or trade secrets, whether or not patentable or registrable under copyright or similar laws. At the Company’s expense, you agree to execute all documents and take all actions necessary or reasonably requested by the Company to document, perfect or assign the Company’s rights to Intellectual Property. Further, if you fail or refuse to execute any such instruments, you hereby appoint the Company as your attorney-in-fact (this appointment to be irrevocable and a power coupled with an interest) to act on your behalf and to execute such documents.

Upon the Company’s request at and after such time as your term as a Director terminates, you agree to return, and will not keep in your possession, recreate or deliver to any third party, any and all documents and/or electronic files containing Confidential Information.

 

AVITA Medical

28159 Avenue Stanford, Suite 220 Valencia, CA 91355

P +1(661) 367-9170 l f +1 (661) 367-9180 l avitamedical.com

LOGO

 

7.

Indemnification.

The Company will agree to defend and indemnify you and hold you harmless against liability that you incur within the scope of your service as a Director of the Company to the fullest extent provided under Delaware law and pursuant to and in accordance with all of the terms and conditions contained in the Indemnification Agreement on the Company’s standard form to be separately provided to you, which is to be executed and delivered by you and the Company upon execution and delivery of this letter agreement. The Company currently holds Directors & Officers Liability coverage with Side A Difference in Conditions coverage of personal asset protection for a director or officer for non-indemnifiable claims as well as coverage B for corporate asset protection for amounts it pays to a director or officer through indemnification and coverage C which provides corporate asset protection for securities claims against the company for a total $30M limit.

 

8.

Publicity.

You and the Company agree to cooperate with each other to create any and all appropriate public or promotional announcements or press releases concerning our relationship.

 

9.

Term and Termination.

This letter agreement will commence on the Effective Date and will continue until such time as your term as a Director terminates. Upon such termination all our rights and duties towards each other shall cease, except that this Section 9 and Sections 5, 6, 7 and 10 shall survive termination of this letter agreement.

 

10.

Other Provisions.

Entire Agreement; Governing Law. This letter agreement constitutes the entire agreement between you and the Company and supersedes and replaces any prior or contemporaneous agreements, representations or understandings, whether written, oral or implied, between you and the Company. This letter agreement will be interpreted, construed and enforced in all respects in accordance with the laws of the State of Delaware, without regard to its conflict of laws rules.

Severability; Counterparts. If any provision of this letter agreement is declared by any court of competent jurisdiction to be illegal, void or unenforceable, all other provisions will not be affected and will remain in full force and effect. This letter agreement may be executed in counterparts, each of which is an original and which together constitute a single agreement.

Equitable Relief. You understand that monetary damages will not adequately compensate the Company for a breach of your obligations. Accordingly, you agree that the Company may specifically enforce this letter agreement and that the Company will be entitled to seek a temporary or permanent injunction or restraining order to prevent any breach or threatened breach of your obligations under this letter agreement. You thus hereby waive any claim or defense that there is an adequate remedy at law for such breach or threatened breach and further agree that no bond or other security will be required in obtaining such equitable relief.

 

AVITA Medical

28159 Avenue Stanford, Suite 220 Valencia, CA 91355

P +1(661) 367-9170 l f +1 (661) 367-9180 l avitamedical.com

LOGO

 

Assignment. You may not assign your rights or obligations under this letter agreement without the Company’s prior written consent. You understand that the Company may assign this letter agreement without your consent to any entity (i) resulting from any merger, consolidation or other reorganization involving the Company, including, without limitation, a merger or other reorganization for the purpose of changing the Company’s domicile, or (ii) to which the Company transfers all or substantially all of its assets.

[Signatures on following page]

 

AVITA Medical

28159 Avenue Stanford, Suite 220 Valencia, CA 91355

P +1(661) 367-9170 l f +1 (661) 367-9180 l avitamedical.com

LOGO

 

Please acknowledge your agreement to these terms by signing and dating a copy of this letter agreement where indicated and returning it to the Company at our address listed below.

 

Sincerely,
AVITA Medical, Inc.
By:   /s/ James Corbett
Name:   James Corbett
Title:   Chief Executive Officer
Company Address:

28I 59 Avenue Stanford, Suite 220

Valencia, California 91355

 

AGREED AND ACKNOWLEDGED:      
     
/s/ Robert McNamara   

Date: March 23, 2023

   
(Signature)
Robert McNamara      
(Print Name)      
Address:      
       
       

 

AVITA Medical

28159 Avenue Stanford, Suite 220 Valencia, CA 91355

P +1(661) 367-9170 l f +1 (661) 367-9180 l avitamedical.com

EX-99.1 3 d468715dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

 

LOGO

AVITA Medical Appoints New Non-Executive Member to the Board of Directors

March 23, 2023

VALENCIA, Calif. and MELBOURNE, Australia, March 23, 2023 (GLOBE NEWSWIRE) — AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, announced today the appointment of Robert McNamara to its Board of Directors, effective April 1, 2023.

Mr. McNamara is an accomplished senior executive with over 25 years of leadership experience in public and privately held companies in the medical device and technology industries. His extensive experience in operations and financial management spans across early stage, high growth, and mature companies. He is currently a member of the Board of Directors and Chair of Audit Committee for Axonics Modulation Technologies and Teknova. Additionally, Mr. McNamara is a member of the Board of Directors and Chair of Compensation Committee for Xtant Medical Holdings. Prior to these appointments, Mr. McNamara served as Executive Vice President, Chief Financial Officer of LDR Holding/Spine. Prior to this role, he served as the Chief Financial Officer of three publicly traded medical device companies Accuray, Somnus Medical Technologies, and Target Therapeutics. Mr. McNamara holds a Bachelor of Science in Accounting from the University of San Francisco and an MBA. from The Wharton School, University of Pennsylvania.

“We are thrilled to welcome Bob to our Board of Directors,” said Jim Corbett, Chief Executive Officer of AVITA Medical. “Bob further strengthens our Board with his demonstrated success in the global operations and financial management of publicly held medical device companies. His executive leadership experience will be invaluable as we continue to execute on growth objectives.”

Authorized for release by the Chief Executive Officer of AVITA Medical, Inc.

ABOUT AVITA MEDICAL, INC.

AVITA Medical® is a regenerative medicine company leading the development and commercialization of devices and autologous cellular therapies for skin restoration. The RECELL® System technology platform, approved by the FDA for the treatment of acute thermal burns in both adults and children, harnesses the regenerative properties of a patient’s own skin to create Spray-On Skin™ cells. Delivered at the point-of-care, RECELL enables improved clinical outcomes and validated cost savings. RECELL is the catalyst of a new treatment paradigm and AVITA Medical is leveraging its proven and differentiated capabilities to develop first-in-class cellular therapies for multiple indications, including soft tissue repair and repigmentation of stable vitiligo lesions.

AVITA Medical’s first U.S. product, the RECELL System, was approved by the U.S. Food and Drug Administration (FDA) in September 2018. The RECELL System is approved for acute partial-thickness thermal burn wounds in patients 18 years of age and older or application in combination with meshed autografting for acute full-thickness thermal burn wounds in pediatric and adult patients. In February 2022, the FDA reviewed and approved the PMA supplement for RECELL Autologous Cell Harvesting Device, an enhanced RECELL System aimed at providing clinicians a more efficient user experience and simplified workflow.

The RECELL System is used to prepare Spray-On Skin™ Cells using a small amount of a patient’s own skin, providing a new way to treat severe burns, while significantly reducing the amount of donor skin required. The RECELL System is designed to be used at the point of care alone or in combination with autografts depending on the depth of the burn injury. Compelling data from randomized, controlled clinical trials conducted at major U.S. burn centers and real-world use in more than 15,000 patients globally, reinforce that the RECELL System is a significant advancement over the current standard of care for burn patients and offers benefits in clinical outcomes and cost savings. Healthcare professionals should read the INSTRUCTIONS FOR USE – RECELL Autologous Cell Harvesting Device (https://recellsystem.com) for a full description of indications for use and important safety information including contraindications, warnings, and precautions.

In international markets, our products are approved under the RECELL System brand to promote skin healing in a wide range of applications including burns, soft tissue repair, vitiligo, and aesthetics. The RECELL System is TGA-registered in Australia, received CE-mark approval in Europe and has PMDA approval in Japan.

To learn more, visit www.avitamedical.com.

FOR FURTHER INFORMATION:

 

Investors & Media

AVITA Medical, Inc.

Jessica Ekeberg

Phone +1-661-904-9269

investor@avitamedical.com

media@avitamedical.com

EX-101.SCH 4 rcel-20230322.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 5 rcel-20230322_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company Entity Ex Transition Period Entity Ex Transition Period EX-101.PRE 6 rcel-20230322_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 7 g468715g0328001117210.jpg GRAPHIC begin 644 g468715g0328001117210.jpg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end GRAPHIC 8 g468715snap2.jpg GRAPHIC begin 644 g468715snap2.jpg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htm IDEA: XBRL DOCUMENT v3.23.1
Document and Entity Information
Mar. 22, 2023
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001762303
Document Type 8-K
Document Period End Date Mar. 22, 2023
Entity Registrant Name AVITA Medical, Inc.
Entity Incorporation State Country Code DE
Entity File Number 001-39059
Entity Tax Identification Number 85-1021707
Entity Address, Address Line One 28159 Avenue Stanford
Entity Address, Address Line Two Suite 220
Entity Address, City or Town Valencia
Entity Address, State or Province CA
Entity Address, Postal Zip Code 91355
City Area Code 661
Local Phone Number 367.9170
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, par value $0.0001 per share
Trading Symbol RCEL
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Entity Ex Transition Period false
XML 10 d468715d8k_htm.xml IDEA: XBRL DOCUMENT 0001762303 2023-03-22 2023-03-22 false 0001762303 8-K 2023-03-22 AVITA Medical, Inc. DE 001-39059 85-1021707 28159 Avenue Stanford Suite 220 Valencia CA 91355 661 367.9170 false false false false Common Stock, par value $0.0001 per share RCEL NASDAQ true false EXCEL 11 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

U8<.&7J/P$ #P" / " 8$0 !X;"]W;W)K8F]O M:RYX;6Q02P$"% ,4 " !@@GM6)!Z;HJT #X 0 &@ M@ 'M$0 >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4 " !@ M@GM699!YDAD! #/ P $P @ '2$@ 6T-O;G1E;G1?5'EP =97-=+GAM;%!+!08 "0 ) #X" <% ! end XML 12 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 13 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 1 24 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://avitamedical.com//20230322/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d468715d8k.htm d468715dex101.htm d468715dex991.htm rcel-20230322.xsd rcel-20230322_lab.xml rcel-20230322_pre.xml http://xbrl.sec.gov/dei/2022 true false JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d468715d8k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 24 }, "contextCount": 1, "dts": { "inline": { "local": [ "d468715d8k.htm" ] }, "labelLink": { "local": [ "rcel-20230322_lab.xml" ] }, "presentationLink": { "local": [ "rcel-20230322_pre.xml" ] }, "schema": { "local": [ "rcel-20230322.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/naics/2022/naics-2022.xsd" ] } }, "elementCount": 25, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 24, "memberCustom": 0, "memberStandard": 0, "nsprefix": "rcel", "nsuri": "http://avitamedical.com/20230322", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "d468715d8k.htm", "contextRef": "duration_2023-03-22_to_2023-03-22", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "menuCat": "Cover", "order": "1", "role": "http://avitamedical.com//20230322/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "d468715d8k.htm", "contextRef": "duration_2023-03-22_to_2023-03-22", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://avitamedical.com//20230322/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://avitamedical.com//20230322/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://avitamedical.com//20230322/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://avitamedical.com//20230322/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://avitamedical.com//20230322/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://avitamedical.com//20230322/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://avitamedical.com//20230322/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://avitamedical.com//20230322/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://avitamedical.com//20230322/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://avitamedical.com//20230322/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://avitamedical.com//20230322/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://avitamedical.com//20230322/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://avitamedical.com//20230322/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://avitamedical.com//20230322/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://avitamedical.com//20230322/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://avitamedical.com//20230322/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://avitamedical.com//20230322/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://avitamedical.com//20230322/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://avitamedical.com//20230322/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://avitamedical.com//20230322/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://avitamedical.com//20230322/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://avitamedical.com//20230322/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://avitamedical.com//20230322/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://avitamedical.com//20230322/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 17 0001193125-23-080474-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-23-080474-xbrl.zip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end